Intrinsiqq
Oruka Therapeutics, Inc. logo

Oruka Therapeutics, Inc. Financials

ORKA

⊜ Compare

All currency values in $ millions unless otherwise noted

Scroll

Showing 6 of 18 available years
Income Statement
TTM
DEC 2025
3:1 split
DEC 2024
~5.2:1 split
FEB 2024
~2.7:1 split
DEC 2023
DEC 2022
Revenues
Revenue$0–––$0$0
General & Administrative–$21––$6$6
Research & Development–$101––$1$5
Total Operating Expenses$32$122––$7$11
Operating Income-$32-$122––-$7-$11
Non-Operating
Net Interest Expense–$17––––
Other Non-Operating Income (Expense)–-$0––––
EBT (Earnings Before Tax)–-$105––––
Income Tax Expense––––$0$0
Net Income
Net Income-$27-$105––-$5-$10
Per Share Data
Revenue Per Share$0.00–––$0.00$0.00
EPS (Basic)-$10.78-$2.16-$3.87–-$4.44-$8.28
EPS (Diluted)-$10.78-$2.16-$3.87–-$4.44-$8.28
Weighted Avg Shares (Basic)14.5M–16.8M–14.4M14.4M
Weighted Avg Shares (Diluted)14.5M–16.8M–14.4M14.4M
Shares Outstanding1.2M48.7M16.8M3.2M1.2M1.2M

Oruka Therapeutics (ORKA) financials: revenue, profit and margins

Oruka Therapeutics (ORKA) generated about n/a in revenue and -$133 million in net income over the trailing twelve months. Figures are from SEC filings; this is analysis, not investment advice.

Frequently asked

Is Oruka Therapeutics profitable?+

Oruka Therapeutics reported about -$133 million in net loss over the trailing twelve months. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.

How the market compares: How many US companies are profitable

SourceFinancial statements computed from the 10-Q filed 31 Jul 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 11 Aug 2026. How this is calculated.

Fiscal year ends Dec.

Peers

Pharmaceutical Preparations · Pick stocks to compare with ORKA

CompareIntrinsic value
NKTXNkarta Inc.
$1.56-6.02%10
TNXPTonix Pharmaceuticals Holding Corp
$5.09-3.60%40
SCYXScynexis, Inc.
$3.72-3.63%40
HROWHarrow Inc.
$28.24-5.84%46
HRTXHeron Therapeutics Inc.
$0.28-3.45%36
RCKTRocket Pharmaceuticals Inc.
$2.44-3.94%10
BBIOBridgeBio Pharma, Inc.
$74.95+5.97%30
LGNDLigand Pharmaceuticals Inc.
$322.75+1.71%36

Held by ETFs

ORKA is in 63 US ETFs. The largest of them, with ORKA's weight in each:

Spot a number that looks wrong? Check it in ORKA's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing ORKA

Create a free account and get 14 days of Premium: every stock and every tool.

  • Unlimited stocks
  • Stock screener
  • Portfolio tracker
  • Editable DCF
  • Compare side by side
  • Unlimited alerts

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

SectorsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.